Tag: AWAKN - Page 4 - Psychedelic Alpha

Read more about the article Awakn Acquires Proprietary Next Generation MDMA and Ketamine Data from Prof. David Nutt

Awakn Acquires Proprietary Next Generation MDMA and Ketamine Data from Prof. David Nutt

Post published:March 9, 2021
Post category:Press Release

Read more about the article Awakn Announces Exclusive License Deal with the University of Exeter to Commercialise the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) Intervention Validated in a Phase II Clinical Trial

Awakn Announces Exclusive License Deal with the University of Exeter to Commercialise the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) Intervention Validated in a Phase II Clinical Trial

Post published:March 2, 2021
Post category:Press Release

Read more about the article Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial

Awakn Chief Medical Officer, Dr. Ben Sessa, Announces Results of the World’s First ‘MDMA in Alcohol Use Disorder’ Clinical Trial

Post published:February 22, 2021
Post category:Press Release

Read more about the article Awakn Appoints James Collins, Ex-Accenture Strategy MD, as Chief Operating Officer

Awakn Appoints James Collins, Ex-Accenture Strategy MD, as Chief Operating Officer

Post published:January 25, 2021
Post category:Press Release

Read more about the article Awakn Strengthens Scientific and Medical Leadership with Appointment of Chief Science Officer and Head of Ketamine Alcohol Use Disorder Practice

Awakn Strengthens Scientific and Medical Leadership with Appointment of Chief Science Officer and Head of Ketamine Alcohol Use Disorder Practice

Post published:January 19, 2021
Post category:Press Release

Read more about the article Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder

Awakn Life Sciences Appoints CRO to Conduct Phase II Study of MDMA as a Treatment for Alcohol Use Disorder

Post published:January 15, 2021
Post category:Press Release

Read more about the article Celia Morgan, Professor of Psychopharmacology at University of Exeter and Leading Ketamine Investigator, Joins AWAKN Life Sciences

Celia Morgan, Professor of Psychopharmacology at University of Exeter and Leading Ketamine Investigator, Joins AWAKN Life Sciences

Post published:October 2, 2020
Post category:Press Release

Read more about the article Dr. Matthew Johnson Joins AWAKN Life Sciences

Dr. Matthew Johnson Joins AWAKN Life Sciences

Post published:September 3, 2020
Post category:Press Release

Read more about the article AWAKN Life Sciences Partners with Drug Science in the UK

AWAKN Life Sciences Partners with Drug Science in the UK

Post published:July 17, 2020
Post category:Press Release

Read more about the article Professor David Nutt Joins AWAKN Life Sciences

Professor David Nutt Joins AWAKN Life Sciences

Post published:July 7, 2020
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.